Drug Trial Radar · NCT04798638
A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Dec 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Apr 30, 2021
Primary completion
Sep 9, 2021
Study completion Sep 9, 2021
Sponsor
- Lead sponsor
- TYK Medicines, IncIndustry
- Sponsor type
- Industry
- First posted
- Mar 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To assess the pharmacokinetics of TY-9591 tablets and Osimertinib Mesylate tablets after a single fasting administration and the effect of food on the pharmacokinetics of TY-9591 tablets in healthy volunteers.
Conditions
- Healthy Volunteers
Interventions
TY-9591 Tablets under Fasted Condition - Arm1Drug
Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
Osimertinib Mesylate Tablets under Fasted Condition - Arm1Drug
Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
TY-9591 Tablets after a High-fat Meal - Arm1Drug
Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
Osimertinib Mesylate Tablets under Fasted Condition - Arm2Drug
Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
TY-9591 Tablets under Fasted Condition - Arm2Drug
Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
TY-9591 Tablets after a High-fat Meal - Arm2Drug
Phase 2 (period 3) allocated high-fat meal prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax of TY-9591 and its metabolitesTime frame: Blood samples are collected at pre-dose (within 1 hour) and 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 hours post-dose.
- Cmax of Osimertinib and its metabolitesTime frame: Blood samples are collected at pre-dose (within 1 hour) and 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 hours post-dose.
- AUC(0-72h) of TY-9591 and its metabolitesTime frame: Blood samples are collected at pre-dose (within 1 hour) and 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 hours post-dose.
- AUC(0-72h) of Osimertinib and its metabolitesTime frame: Blood samples are collected at pre-dose (within 1 hour) and 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336 hours post-dose.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hunan Provincial Tumor Hospital
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.